New drug combo for advanced colorectal cancer with BRAF mutation
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has a specific genetic change called BRAF V600E. The treatment includes a targeted therapy (ivosidenib) plus chemotherapy and a pain-relief drug (celecoxib). It is for people whose cancer has stopped responding to previous treatments, including BRAF-targeted therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have colorectal cancer that has spread to other parts of the body.
- Your tumor has a specific genetic change called BRAF V600E.
- You have already tried at least one line of chemotherapy (like FOLFOX or FOLFIRI) and it stopped working or caused too many side effects.
- You have also tried a BRAF-targeted therapy (like vemurafenib, dabrafenib, or encorafenib) and it did not work.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial compares two combinations of drugs for people with a certain type of advanced colorectal cancer that has progressed after initial treatment. It aims to see if one combination works better than the other, potentially offering a new option for second-line therapy.
This trial tests a new combination of drugs (IB-FOLFIRI) for people with metastatic colorectal cancer that has a specific gene change called BRAF V600E. It is for those whose cancer has grown after at least one prior treatment and who have not had irinotecan stop working.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.